Apoptosis, cellular division or mitotic catastrophe? Effects of kinase inhibition and DNa damage in lung cancer cells
Author: Hemström, Anna Therése Helén
Date: 2007-01-28
Location: Rockefeller, Nobels väg 11, Karolinska Institutet, Solna
Time: 09.00
Department: Institutet för miljömedicin (IMM) / Institute of Enviromental Medicine
View/ Open:
Thesis (556.4Kb)
Abstract
Non-small cell lung cancer (NSCLC) cells are generally characterized by a
low response to conventional anti-cancer agents, such as DNA-damaging
drugs. Treatments that induce DNA damage relies on cellular signalling
resulting in the induction of growth arrest and apoptotic cell death.
Deregulation of apoptosis contributes to resistance and failure of death
execution may occur even in cases when all components of the apoptotic
machinery are present in the cell. One possible reason for the inhibition
of cell death is aberrant signalling of kinases, favouring cell survival.
The main goal of this project was to understand the function of the
apoptotic machinery in human lung cancer cells resistant to anti-cancer
treatment and to investigate if the efficiency of the killing of these
cells could be modified by using inhibitors of phosphorylation-based
signalling. The NSCLC cell line U1810 is resistant to induction of
apoptosis by conventional DNA damage-inducing anti-cancer treatments;
however these cells are sensitive to the action of the broad range
protein kinase inhibitor staurosporine (STS).
The two STS analogues PKC 412 and Ro 31-8220 are more specific protein kinase C (PKC) inhibitors compared to STS. The anti-tumour effects of PKC 412 and Ro 31-8220, when used alone or in combination with DNA-damaging treatments, were investigated. Ro 31-8220 neither induced apoptosis when used alone, nor sensitized cells to treatment with the DNA-damaging drug etoposide. PKC 412 induced death of a small number of U1810 cells, and sensitized cells to gamma radiation and etoposide. The difference in cell death induction upon treatment with Ro 31-8220 and PKC 412 could not be explained by a difference in the potency of PKC inhibition of the two STS analogues. Interestingly, Ro 31-8220 increased, whereas PKC 412 decreased, activity-related phosphorylation of the protein kinase Akt. Moreover, etoposide increased phosphorylation of Akt, which could be reversed by PKC 412. Inhibitors (wortmannin and LY-294002) of the Akt upstream activator PI3-kinase had a similar effect on U1810 cell as PKC 412. LY-294002, wortmannin and PKC 412 promoted apoptosis in a cell cycle dependent manner. LY-294002 and wortmannin induced apoptosis in late mitosis, whereas PKC 412 treatment provoked apoptosis in early mitosis and also induced formation of multinucleated cells. LY-294002 and wortmannin, in a similar manner as PKC 412, sensitized U1810 as well as H157 NSCLC cells to etoposide. PD 98059, which is an inhibitor of the protein kinase MEK, could not induce apoptosis when used alone in neither of the two NSCLC cell lines. However, in H157 cells PD 98059 enhanced apoptosis induced by treatment with etoposide in combination with wortmannin or LY-294002.
STS, PKC 412, etoposide or etoposide in combination with PKC 412 induced apoptosis at different time points and with different potency in U1810 cells. All four treatments resulted in cellular activation of caspase-3-like activity. Caspases cleave many proteins and are often determining apoptosis. Nevertheless, irrespective of the type of apoptosis-inducing treatment used, an inhibitor of caspase activity could not prevent apoptosis-related nuclear condensation in U1810 cells. Instead, upon all four different treatments, nuclear apoptosis was dependent upon release of Apoptosis inducing factor (AIF) from mitochondria. When etoposide and PKC 412 were combined, there was an increase in the release of AIF from mitochondria of U1810 cells. By using inhibitors of Poly(ADP-ribose) polymerase (PARP) we could show that release of AIF from mitochondria upon treatment with etoposide alone, or in combination with PKC 412, demands PARP activity. Single treatment with PKC 412 induced AIF release and nuclear apoptosis independently of PARP. PKC 412 decreased inhibitory phosphorylation of the protein Bad, a protein which upon activation is known to promote release of mitochondrial proteins.
Collectively, our data suggest that etoposide and PKC 412 complement each other for the induction of apoptosis in NSCLC cells. Both drugs, in different manners, induce upstream mitochondrial events that promote increased release of mitochondrial AIF which determines apoptosis. PKC 412, possibly through inhibition of PI3-kinase downstream signalling, increases death of NSCLC cells through provoking mitotic catastrophe, and possibly also through activation of Bad. Etoposide increases cell death through induction of PARP-dependent release of AIF from mitochondria.
The two STS analogues PKC 412 and Ro 31-8220 are more specific protein kinase C (PKC) inhibitors compared to STS. The anti-tumour effects of PKC 412 and Ro 31-8220, when used alone or in combination with DNA-damaging treatments, were investigated. Ro 31-8220 neither induced apoptosis when used alone, nor sensitized cells to treatment with the DNA-damaging drug etoposide. PKC 412 induced death of a small number of U1810 cells, and sensitized cells to gamma radiation and etoposide. The difference in cell death induction upon treatment with Ro 31-8220 and PKC 412 could not be explained by a difference in the potency of PKC inhibition of the two STS analogues. Interestingly, Ro 31-8220 increased, whereas PKC 412 decreased, activity-related phosphorylation of the protein kinase Akt. Moreover, etoposide increased phosphorylation of Akt, which could be reversed by PKC 412. Inhibitors (wortmannin and LY-294002) of the Akt upstream activator PI3-kinase had a similar effect on U1810 cell as PKC 412. LY-294002, wortmannin and PKC 412 promoted apoptosis in a cell cycle dependent manner. LY-294002 and wortmannin induced apoptosis in late mitosis, whereas PKC 412 treatment provoked apoptosis in early mitosis and also induced formation of multinucleated cells. LY-294002 and wortmannin, in a similar manner as PKC 412, sensitized U1810 as well as H157 NSCLC cells to etoposide. PD 98059, which is an inhibitor of the protein kinase MEK, could not induce apoptosis when used alone in neither of the two NSCLC cell lines. However, in H157 cells PD 98059 enhanced apoptosis induced by treatment with etoposide in combination with wortmannin or LY-294002.
STS, PKC 412, etoposide or etoposide in combination with PKC 412 induced apoptosis at different time points and with different potency in U1810 cells. All four treatments resulted in cellular activation of caspase-3-like activity. Caspases cleave many proteins and are often determining apoptosis. Nevertheless, irrespective of the type of apoptosis-inducing treatment used, an inhibitor of caspase activity could not prevent apoptosis-related nuclear condensation in U1810 cells. Instead, upon all four different treatments, nuclear apoptosis was dependent upon release of Apoptosis inducing factor (AIF) from mitochondria. When etoposide and PKC 412 were combined, there was an increase in the release of AIF from mitochondria of U1810 cells. By using inhibitors of Poly(ADP-ribose) polymerase (PARP) we could show that release of AIF from mitochondria upon treatment with etoposide alone, or in combination with PKC 412, demands PARP activity. Single treatment with PKC 412 induced AIF release and nuclear apoptosis independently of PARP. PKC 412 decreased inhibitory phosphorylation of the protein Bad, a protein which upon activation is known to promote release of mitochondrial proteins.
Collectively, our data suggest that etoposide and PKC 412 complement each other for the induction of apoptosis in NSCLC cells. Both drugs, in different manners, induce upstream mitochondrial events that promote increased release of mitochondrial AIF which determines apoptosis. PKC 412, possibly through inhibition of PI3-kinase downstream signalling, increases death of NSCLC cells through provoking mitotic catastrophe, and possibly also through activation of Bad. Etoposide increases cell death through induction of PARP-dependent release of AIF from mitochondria.
List of papers:
I. Gallego MA, Joseph B, Hemstrom TH, Tamiji S, Mortier L, Kroemer G, Formstecher P, Zhivotovsky B, Marchetti P. (2004). Apoptosis-inducing factor determines the chemoresistance of non-small-cell lung carcinomas. Oncogene. 23(37): 6282-91
Pubmed
II. Hemstrom TH, Joseph B, Schulte G, Lewensohn R, Zhivotovsky B. (2005). PKC 412 sensitizes U1810 non-small cell lung cancer cells to DNA damage. Exp Cell Res. 305(1): 200-13
Pubmed
III. Hemstrom TH, Sandstrom M, Zhivotovsky B. (2006). Inhibitors of the PI3-kinase/Akt pathway induce mitotic catastrophe in non-small cell lung cancer cells. Int J Cancer. 119(5): 1028-38
Pubmed
IV. Hemstrom TH, Sandstrom M, Joseph B, Zhivotovsky B (2006). PARP inhibitors rescue non-small cell lung cancer cells from etoposide-induced apoptosis by regulation of mitochondrial release of Apoptosis-inducing factor. [Manuscript]
I. Gallego MA, Joseph B, Hemstrom TH, Tamiji S, Mortier L, Kroemer G, Formstecher P, Zhivotovsky B, Marchetti P. (2004). Apoptosis-inducing factor determines the chemoresistance of non-small-cell lung carcinomas. Oncogene. 23(37): 6282-91
Pubmed
II. Hemstrom TH, Joseph B, Schulte G, Lewensohn R, Zhivotovsky B. (2005). PKC 412 sensitizes U1810 non-small cell lung cancer cells to DNA damage. Exp Cell Res. 305(1): 200-13
Pubmed
III. Hemstrom TH, Sandstrom M, Zhivotovsky B. (2006). Inhibitors of the PI3-kinase/Akt pathway induce mitotic catastrophe in non-small cell lung cancer cells. Int J Cancer. 119(5): 1028-38
Pubmed
IV. Hemstrom TH, Sandstrom M, Joseph B, Zhivotovsky B (2006). PARP inhibitors rescue non-small cell lung cancer cells from etoposide-induced apoptosis by regulation of mitochondrial release of Apoptosis-inducing factor. [Manuscript]
Issue date: 2007-01-07
Rights:
Publication year: 2007
ISBN: 978-91-7357-031-2
Statistics
Total Visits
Views | |
---|---|
Apoptosis, ...(legacy) | 854 |
Apoptosis, ... | 120 |
Total Visits Per Month
October 2023 | November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | April 2024 | |
---|---|---|---|---|---|---|---|
Apoptosis, ... | 2 | 0 | 0 | 0 | 4 | 0 | 0 |
File Visits
Views | |
---|---|
thesis.pdf(legacy) | 400 |
thesis.pdf | 104 |
thesis.pdf.txt(legacy) | 2 |
Top country views
Views | |
---|---|
United States | 387 |
Sweden | 75 |
China | 74 |
Germany | 68 |
South Korea | 20 |
Finland | 18 |
Ireland | 12 |
Russia | 12 |
United Kingdom | 11 |
Denmark | 10 |
Top cities views
Views | |
---|---|
Romeo | 31 |
Sunnyvale | 31 |
Beijing | 28 |
Kiez | 27 |
Stockholm | 20 |
Seoul | 14 |
Helsinki | 11 |
Ashburn | 8 |
Dublin | 8 |
London | 7 |